Search

Supplemental material, sj-docx-1-tar-10.1177_17534666231172924 for Predictors of poor clinical outcomes including in-hospital death and low ability to perform activities of daily living at discharge in hospitalized patients with chronic obstructive pulmonary disease exacerbation by Yurina Murakami, Hideki Yasui, Jun Sato, Tomohiro Uto, Naoki Inui, Takafumi Suda and Shiro Imokawa in Therapeutic Advances in Respiratory Disease

Background and objective: Though idiopathic pulmonary fibrosis (IPF) has worse outcomes compared to most malignancies, patients with IPF receive poor access to optimal palliative care. This study aimed to characterise the practice of pulmonologist's regarding palliative care and end of life communication for patients with IPF and identify perceived difficulties and barriers thereto.Methods: Self-administered questionnaires were sent by mail to representative pulmonologists from Shizuoka prefecture, Japan. Physician-reported practice, difficulties, timing of end of life communication and barriers related to palliative care were investigated.Results: Among the 135 participants, 130 (96%) completed the questionnaire. Most of the participants reported that patients with IPF complained of dyspnoea and cough. However, less morphine was prescribed for IPF than for lung cancer. The participants experienced greater difficulty in providing palliative care for IPF than for lung cancer. Moreover, actual end of life discussions in patients with IPF were conducted later than the physician-perceived ideal timing. Among the barriers identified, few established treatment and difficulty in predicting prognosis [odds ratio (OR) 2.0; p=0.04], discrepancies in understanding and care goals among patients, family and medical staff (OR 2.2; p=0.03) and inadequate communication about goal of care (OR 2.3; p=0.003) were significantly associated with the physician-perceived difficulties in providing palliative care for patients with IPF.Conclusions: Pulmonologists experienced greater difficulty in providing palliative care to patients with IPF than to those with lung cancer. Clinical studies on the optimal palliative care for patients with IPF are urgently required., Key Message: Pulmonologists experienced greater difficulty in providing palliative care to patients with IPF than to those with lung cancer. Clinical studies on the optimal palliative care for patients with IPF are urgently required.

Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. There are no established serum biomarkers for predicting the outcomes of IPF. S100 calcium binding protein A4 (S100A4) is considered a marker of fibroblasts; however, its clinical application remains to be investigated. We evaluated the clinical relevance of S100A4 in IPF patients.Methods: Serum S100A4 levels in 95 consecutive IPF patients and 50 healthy controls (HCs) were measured using enzyme-linked immunosorbent assay. S100A4 expression in lung tissues was determined using immunohistochemistry/immunofluorescence and its association with disease progression (defined as deterioration in lung function or death) and mortality was assessed using Kaplan–Meier method and Cox hazards analysis.Results: Serum S100A4 levels were undetectable in all HCs but were detectable in 26 (27.3%) of the 95 IPF patients (P

Supplemental material, sj-docx-1-taj-10.1177_20406223221108395 for Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study by Keigo Koda, Yasunori Enomoto, Yoichiro Aoshima, Yusuke Amano, Shinpei Kato, Hirotsugu Hasegawa, Takashi Matsui, Koshi Yokomura, Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Meiko Morita, Suguru Kojima, Ayano Watanabe, Yoshiyuki Oyama, Masaki Ikeda, Hideki Kusagaya, Tomohiro Uto, Jun Sato, Shiro Imokawa, Masato Kono, Dai Hashimoto, Yosuke Kamiya, Mikio Toyoshima, Kazuhiro Asada, Masako Morita, Masashi Mikamo, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui and Takafumi Suda in Therapeutic Advances in Chronic Disease

Supplemental material, sj-docx-1-taj-10.1177_20406223221108395 for Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study by Keigo Koda, Yasunori Enomoto, Yoichiro Aoshima, Yusuke Amano, Shinpei Kato, Hirotsugu Hasegawa, Takashi Matsui, Koshi Yokomura, Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Meiko Morita, Suguru Kojima, Ayano Watanabe, Yoshiyuki Oyama, Masaki Ikeda, Hideki Kusagaya, Tomohiro Uto, Jun Sato, Shiro Imokawa, Masato Kono, Dai Hashimoto, Yosuke Kamiya, Mikio Toyoshima, Kazuhiro Asada, Masako Morita, Masashi Mikamo, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui and Takafumi Suda in Therapeutic Advances in Chronic Disease

Additional file 2. Supplementary Tables 1–4: Table 1. Cox proportional hazard analysis of overall survival. Table 2. Cox proportional hazard analysis of acute exacerbations. Table 3. Characteristics of the new clusters derived from Cluster II. Table 4. Diagnosis of IIPs in the new clusters derived from Cluster II.

Additional file 1: Table S1. Reasons for IIPs being unclassified in MDD.

Additional file 1. Supplementary Figures 1–3: Figure 1. Dendrogram of patients with IIPs using cluster analysis. Figure 2. Overall survival in the new clusters derived from Cluster II. Figure 3. Cumulative incidence of acute exacerbations in the new clusters derived from Cluster II.

Additional file 3: Fig. S1. Correlation between BAL lymphocytes and interstitial cell infiltration on histopathological examination in a subgroup of patients without anti-inflammatory drugs.

Additional file 4: Fig. S2. Prognostic impact of BAL lymphocytosis on patients treated with anti-inflammatory drugs at each cut-off value

Additional file 2: Table S2. Environmental exposures, symptoms suggestive of CTD, and serologic markers associated with CTD

Additional file 5: Fig. S3. CART analysis for predicting prognosis.

Additional file 1. Supplementary Figure. Progression-free and overall survival after platinum-based chemotherapy according to four levels of the geriatric nutritional risk index (GNRI).

Supplemental material, Author_Response_2 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Author_response_1 for Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease by Takafumi Koyauchi, Hideki Yasui, Noriyuki Enomoto, Hirotsugu Hasegawa, Hironao Hozumi, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Koshi Yokomura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_1_v.3 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Author_Response_1 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Author_Response_1 for Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis by Yuya Aono, Yutaro Nakamura, Masato Kono, Hidenori Nakamura, Koshi Yokomura, Shiro Imokawa, Mikio Toyoshima, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_1_v.1 for Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease by Takafumi Koyauchi, Hideki Yasui, Noriyuki Enomoto, Hirotsugu Hasegawa, Hironao Hozumi, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Koshi Yokomura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Supplementary_Figure_1 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_2_v.1 for Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease by Takafumi Koyauchi, Hideki Yasui, Noriyuki Enomoto, Hirotsugu Hasegawa, Hironao Hozumi, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Koshi Yokomura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Additional file 5: Fig. S1. IAV RNA levels in organ culture of murine tracheal tissues. Fig. S2. Inactivation of IAV by UV irradiation. Fig. S3. IAV RNA levels in tracheal tissues of WT and TLR3-KO mice. Fig. S4. Changes of CBF by ATP stimulation.

Supplemental material, Aono_et_al_Supplementary_Figures for Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis by Yuya Aono, Yutaro Nakamura, Masato Kono, Hidenori Nakamura, Koshi Yokomura, Shiro Imokawa, Mikio Toyoshima, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Author_Response_2 for Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease by Takafumi Koyauchi, Hideki Yasui, Noriyuki Enomoto, Hirotsugu Hasegawa, Hironao Hozumi, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Koshi Yokomura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_1_v.1 for Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis by Yuya Aono, Yutaro Nakamura, Masato Kono, Hidenori Nakamura, Koshi Yokomura, Shiro Imokawa, Mikio Toyoshima, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Author_Response_3 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_2_v.1 for Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis by Yuya Aono, Yutaro Nakamura, Masato Kono, Hidenori Nakamura, Koshi Yokomura, Shiro Imokawa, Mikio Toyoshima, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_2_v.2 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Reviewer_1_v.1 for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Supplemental material, Tables_supplement for Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis by Noriyuki Enomoto, Hyogo Naoi, Yuya Aono, Mineo Katsumata, Yasuoki Horiike, Hideki Yasui, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura and Takafumi Suda in Therapeutic Advances in Respiratory Disease

Masato Karayama,1 Naoki Inui,1,2 Hideki Yasui,1 Masato Kono,1 Hironao Hozumi,1 Yuzo Suzuki,1 Kazuki Furuhashi,1 Dai Hashimoto,1 Noriyuki Enomoto,1 Tomoyuki Fujisawa,1 Yutaro Nakamura,1 Hiroshi Watanabe,2 Takafumi Suda11Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan; 2Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, JapanPurpose: The diagnosis and severity of chronic obstructive pulmonary disease (COPD) are defined by airflow limitation using spirometry. However, COPD has diverse clinical features, and several phenotypes based on non-spirometric data have been investigated. To identify novel phenotypes of COPD using radiologic data obtained by three-dimensional computed tomography (3D-CT).Patients and methods: The inner luminal area and wall thickness of third- to sixth-generation bronchi and the percentage of the low-attenuation area (less than −950 HU) of the lungs were measured using 3D-CT in patients with COPD. Using the radiologic data, hierarchical clustering was performed. Respiratory reactance and resistance were measured to evaluate functional differences among the clusters.Results: Four clusters were identified among 167 patients with COPD: Cluster I, mild emphysema with severe airway changes, severe airflow limitation, and high exacerbation risk; Cluster II, mild emphysema with moderate airway changes, mild airflow limitation, and mild dyspnea; Cluster III, severe emphysema with moderate airway changes, severe airflow limitation, and increased dyspnea; and Cluster IV, moderate emphysema with mild airway changes, mild airflow limitation, low exacerbation risk, and mild dyspnea. Cluster I had the highest respiratory resistance among the four clusters. Clusters I and III had higher respiratory reactance than Clusters II and IV.Conclusions: The 3D-CT-based radiologic phenotypes were associated with the clinical features of COPD. Measurement of respiratory resistance and reactance may help to identify phenotypic differences.Keywords: airway, chronic obstructive pulmonary disease, clustering analysis, emphysema, phenotype, three-dimensional computed tomography

Supplementary_Table_AE-CTD-IP_662018 for Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis by Noriyuki Enomoto, Yoshiyuki Oyama, Yasunori Enomoto, Hideki Yasui, Masato Karayama, Masato Kono, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura, and Takafumi Suda in Chronic Respiratory Disease

APSIPA ASC 2009: Asia-Pacific Signal and Information Processing Association, 2009 Annual Summit and Conference. 4-7 October 2009. Sapporo, Japan. Poster session: Automatic Speech Recognition (6 October 2009)., We propose a noise robust speech recognition method based on combining novel features extracted from fundamental frequency (F0) information and spectral subtraction. F0 features have been shown to be effective in speech recognition in noisy environments. Recently, F0 features obtained by Hough transform were developed for concatenated digit recognition and significantly improved recognition performance of noisy speech. This paper proposes novel features based on Hough transform for large-vocabulary continuous speech recognition. In addition, spectral subtraction is applied before Hough transform to remove static noise. The proposed method was tested using the Japanese Newspaper Article Sentences (JNAS) database. Word accuracy was improved in all noise conditions, with the best absolute improvement being 2.6 points in percentage when station noise was added at 10 dB SNR.